Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $179.0 million.

  • Vanda Pharmaceuticals' Short-term Investments fell 3427.17% to $179.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $179.0 million, marking a year-over-year decrease of 3427.17%. This contributed to the annual value of $179.0 million for FY2025, which is 3427.17% down from last year.
  • Vanda Pharmaceuticals' Short-term Investments amounted to $179.0 million in Q4 2025, which was down 3427.17% from $223.7 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Short-term Investments registered a high of $405.4 million during Q3 2022, and its lowest value of $147.3 million during Q1 2023.
  • Moreover, its 5-year median value for Short-term Investments was $295.4 million (2021), whereas its average is $294.7 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 5999.31% in 2023, then surged by 8257.87% in 2024.
  • Over the past 5 years, Vanda Pharmaceuticals' Short-term Investments (Quarter) stood at $380.7 million in 2021, then decreased by 12.85% to $331.8 million in 2022, then decreased by 23.92% to $252.4 million in 2023, then increased by 7.88% to $272.3 million in 2024, then tumbled by 34.27% to $179.0 million in 2025.
  • Its last three reported values are $179.0 million in Q4 2025, $223.7 million for Q3 2025, and $244.6 million during Q2 2025.